Does Kevzara Increase Diverticulitis Risk?
Kevzara (sarilumab), an IL-6 receptor inhibitor for rheumatoid arthritis, carries warnings for gastrointestinal perforations, which include cases involving diverticulitis. The prescribing information notes that events like diverticulitis have occurred in clinical trials and post-marketing reports, often with confounding factors such as NSAID or corticosteroid use. The risk is higher in patients with diverticulitis history or other GI risk factors, prompting recommendations to avoid Kevzara in active diverticulitis and exercise caution otherwise [1][2].
What Trial Data Shows
In the MOBILITY trial (Phase 3, rheumatoid arthritis patients), GI perforations occurred in 0.5% of Kevzara users versus 0.2% on placebo, with some linked to diverticulitis. Pooled safety data across trials reported diverticulitis as a serious adverse event in <1% of patients, typically resolving with treatment interruption. No direct causal link was established, but the label flags it as a class effect for immunosuppressants like Kevzara [1][3].
How It Compares to Other RA Drugs
Similar risks appear with other biologics: Actemra (tocilizumab, same class) has comparable GI perforation rates (0.2-0.5% in trials), while TNF inhibitors like Humira show lower diverticulitis signals but still require monitoring. Steroids amplify risk across all, explaining many cases [1][4].
Who Faces Higher Risk?
Patients over 65, those on NSAIDs/steroids, or with prior diverticulitis/GI disease see elevated incidence. Kevzara's label advises prompt evaluation of abdominal symptoms like pain or fever, with discontinuation if perforation suspected [1][2].
What Doctors Recommend
Screen for GI history pre-treatment; monitor symptoms closely. No routine diverticulitis prophylaxis, but alternatives like JAK inhibitors (e.g., Xeljanz) may have different profiles if risk is a concern [1][5].
Kevzara Patents and Availability
Kevzara's main composition patent (US 8,562,991) expires in 2028, with formulation patents into 2032. No generics yet; biosimilar challenges are pending [6].
[1]: Kevzara Prescribing Information (FDA.gov)
[2]: KEVZARA HCP Safety Info (kevzara.com)
[3]: MOBILITY Trial (NEJM, 2017)
[4]: Actemra Label (FDA.gov)
[5]: ACR RA Guidelines (rheumatology.org)
[6]: DrugPatentWatch.com - Kevzara Patents